Vascular Endothelial Growth Factor (VEGF) Market - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast 2031 - By Product, Technology, Grade, Application, End-user, Region: (North America, Europe, Asia Pacific, Latin America and Middle East and Africa)

Report
440 Pages
January 2024
Region: Global
Fairfield Market Research
ID: 5927534

The global vascular endothelial growth factor (VEGF) market is on the cusp of significant growth, with a valuation of US$ 245 million at the close of 2024. By the end of 2031, the VEGF market is estimated to reach a substantial valuation of US$ 560 million, indicating a highly progressive growth trajectory.

A Pivotal Role in Disease Intervention

The versatility of VEGF molecules and advancements in research exploring their benefits in disease intervention have led to substantial growth in the market. Studies have demonstrated the potential of VEGF in treating renovascular disease (RVD) by coupling it with innovative carrier proteins. Enhanced renal function, reduced vascular resistance, and improved microvascular density have all been associated with VEGF-based treatments.

Investments in clinical trial investigations are expected to increase in the coming years, further bolstering market growth. Additionally, the use of intradermal VEGF-A mRNA in regenerative angiogenesis shows promise as a treatment for ischemic cardiovascular disease and diabetes, expanding the VEGF market from clinical interventions to a consumer-driven market.

Opportunities for VEGF Manufacturers

One of the notable opportunities for VEGF manufacturers lies in the treatment of peripheral vascular diseases. Recent research into gene co-delivery nanoparticles containing VEGF and nerve growth factors has shown promising results in improving blood perfusion, gene co-expression, and stable angiogenesis, offering new treatment options for peripheral vascular diseases.

Poly-l-lactide (PLA) loaded VEGF microparticles with a long-term release structure also hold potential in proangiogenic therapy, reducing the negative effects of multiple administrations and aiding in tissue remodeling, vasculogenesis, and angiogenesis.

The wide range of applications for VEGF presents lucrative opportunities for market players, with a growing trend in demand and sales.

Challenges in VEGF Market Expansion

Despite its potential, the short half-life of VEGF protein and challenges in selecting the route of administration for drug delivery have hindered its clinical success. Overcoming the limitations of VEGF's short half-life and chemical instability remains a challenge in the manufacturing process.

Country-wise Insights

U.S. VEGF Market: The U.S. dominated the North American VEGF market in 2024. Acquisitions by manufacturers and a growing focus on better treatment options have contributed to market growth.

German VEGF Market: Germany held a significant portion of the market share in Europe's vascular endothelial growth factor market in 2024.

The prominent players in Germany are actively expanding their manufacturing centers to offer products at competitive prices within the region, thereby playing a pivotal role in driving the growth of the German market.

China VEGF Market: In 2024, China held a significant market share in the East Asian vascular endothelial growth factor market.

Chinese leaders are increasingly viewing biologic contract manufacturing organizations (CMOs) as a viable option for bio manufacturing. These CMOs offer services to small- and medium-sized companies and invest in GMP facilities, making them an attractive choice.

Furthermore, established companies are expanding their manufacturing facilities, further bolstering the growth of the market in China.

Competitive Landscape

Key companies in the VEGF market include,

Thermo Fisher Scientific Inc.
Merck KGaA
Bio-Rad Laboratories, Inc.
Bio-Techne [R&D Systems, Inc.]
GenScript
Miltenyi Biotec.
Abcam PLC.
Sino Biological Inc.
Cell Signaling Technology, Inc.
ACROBiosystems
STEMCELL Technologies
Creative Bioarray
PeproTech
Applied Biological Materials (ABM) Inc.
GenWay Biotech
Leadgene Biomedical, Inc.
Boster Bio
Prospec-Tany Technogene Ltd.
Proteintech Group, Inc

Key Segments Covered in VEGF Industry Survey

VEGF Market by VEGF Type:

Human VEGF
Mouse VEGF
Rat VEGF
Rabbit VEGF
Others VEGF

VEGF Market by Expression Host:

CHO
E. Coli
HEK
NSO
Insect Cells
Others

VEGF Market by Application:

Cell Culture
Cell-based Therapy
Drug Development
Gene Therapy
Rare Disease treatment
Wound Healing Research
Combination Therapies
Hematology Research
Osteogenesis
Anti-Angiogenic Therapy

VEGF Market by End User:

Pharmaceutical & Biotechnology Companies
Academic Institutes
CMOs & CDMOs
Other End Users
Research Centers & Laboratories
Hospital-attached Laboratories (HALs)

VEGF Market by Region:

North America VEGF Market
Latin America VEGF Market
Europe VEGF Market
South Asia VEGF Market
East Asia VEGF Market
Oceania VEGF Market
Middle East & Africa VEGF Market

This product will be delivered within 1-3 business days.

1. Executive Summary

1.1. Global Vascular Endothelial Growth Factor (VEGF) Market Snapshot
1.2. Future Projections
1.3. Key Market Trends
1.4. Regional Snapshot, by Value, 2023
1.5. Analyst Recommendations

2. Market Overview

2.1. Market Definitions and Segmentations
2.2. Market Dynamics
2.2.1. Drivers
2.2.2. Restraints
2.2.3. Market Opportunities
2.3. Value Chain Analysis
2.4. Porter’s Five Forces Analysis
2.5. COVID-19 Impact Analysis
2.5.1. Supply
2.5.2. Demand
2.6. Impact of Ukraine-Russia Conflict
2.7. Economic Overview
2.7.1. World Economic Projections
2.8. PESTLE Analysis

3. Global Vascular Endothelial Growth Factor (VEGF) Market Outlook, 2018 - 2031

3.1. Global Vascular Endothelial Growth Factor (VEGF) Market Outlook, by VEGF Types, Value (US$ Mn), 2018 - 2031
3.1.1. Key Highlights
3.1.1.1. Human VEGF
3.1.1.2. Mouse VEGF
3.1.1.3. Rat VEGF
3.1.1.4. Rabbit VEGF
3.1.1.5. Others VEGF
3.2. Global Vascular Endothelial Growth Factor (VEGF) Market Outlook, by Application, Value (US$ Mn), 2018 - 2031
3.2.1. Key Highlights
3.2.1.1. Cell Culture
3.2.1.2. Cell-based Therapy
3.2.1.3. Drug Development
3.2.1.4. Gene Therapy
3.2.1.5. Rare Disease treatment
3.2.1.6. Wound Healing Research
3.2.1.7. Combination Therapies
3.2.1.8. Hematology Research
3.2.1.9. Osteogenesis
3.2.1.10. Anti-Angiogenic Therapy
3.3. Global Vascular Endothelial Growth Factor (VEGF) Market Outlook, by Expression Host, Value (US$ Mn), 2018 - 2031
3.3.1. Key Highlights
3.3.1.1. CHO
3.3.1.2. E. Coli
3.3.1.3. HEK
3.3.1.4. NSO
3.3.1.5. Insect Cells
3.3.1.6. Others
3.4. Global Vascular Endothelial Growth Factor (VEGF) Market Outlook, by End User, Value (US$ Mn), 2018 - 2031
3.4.1. Key Highlights
3.4.1.1. Pharmaceutical & Biotechnology Companies
3.4.1.2. Academic Institutes
3.4.1.3. CMOs & CDMOs
3.4.1.4. Other End Users
3.4.1.4.1. Research Centers & Laboratories
3.4.1.4.2. Hospital-attached Laboratories (HALs)
3.5. Global Vascular Endothelial Growth Factor (VEGF) Market Outlook, by Region, Value (US$ Mn), 2018 - 2031
3.5.1. Key Highlights
3.5.1.1. North America
3.5.1.2. Europe
3.5.1.3. Asia Pacific
3.5.1.4. Latin America
3.5.1.5. Middle East & Africa

4. North America Vascular Endothelial Growth Factor (VEGF) Market Outlook, 2018 - 2031

4.1. North America Vascular Endothelial Growth Factor (VEGF) Market Outlook, by VEGF Types, Value (US$ Mn), 2018 - 2031
4.1.1. Key Highlights
4.1.1.1. Human VEGF
4.1.1.2. Mouse VEGF
4.1.1.3. Rat VEGF
4.1.1.4. Rabbit VEGF
4.1.1.5. Others VEGF
4.2. North America Vascular Endothelial Growth Factor (VEGF) Market Outlook, by Application, Value (US$ Mn), 2018 - 2031
4.2.1. Key Highlights
4.2.1.1. Cell Culture
4.2.1.2. Cell-based Therapy
4.2.1.3. Drug Development
4.2.1.4. Gene Therapy
4.2.1.5. Rare Disease treatment
4.2.1.6. Wound Healing Research
4.2.1.7. Combination Therapies
4.2.1.8. Hematology Research
4.2.1.9. Osteogenesis
4.2.1.10. Anti-Angiogenic Therapy
4.3. North America Vascular Endothelial Growth Factor (VEGF) Market Outlook, by Expression Host, Value (US$ Mn), 2018 - 2031
4.3.1. Key Highlights
4.3.1.1. CHO
4.3.1.2. E. Coli
4.3.1.3. HEK
4.3.1.4. NSO
4.3.1.5. Insect Cells
4.3.1.6. Others
4.4. North America Vascular Endothelial Growth Factor (VEGF) Market Outlook, by End User, Value (US$ Mn), 2018 - 2031
4.4.1. Key Highlights
4.4.1.1. Pharmaceutical & Biotechnology Companies
4.4.1.2. Academic Institutes
4.4.1.3. CMOs & CDMOs
4.4.1.4. Other End Users
4.4.1.4.1. Research Centers & Laboratories
4.4.1.4.2. Hospital-attached Laboratories (HALs)
4.5. North America Vascular Endothelial Growth Factor (VEGF) Market Outlook, by Country, Value (US$ Mn), 2018 - 2031
4.5.1. Key Highlights
4.5.1.1. U.S. Vascular Endothelial Growth Factor (VEGF) Market by VEGF Types, Value (US$ Mn), 2018 - 2031
4.5.1.2. U.S. Vascular Endothelial Growth Factor (VEGF) Market Indication, Value (US$ Mn), 2018 - 2031
4.5.1.3. U.S. Vascular Endothelial Growth Factor (VEGF) Market Artery Type, Value (US$ Mn), 2018 - 2031
4.5.1.4. U.S. Vascular Endothelial Growth Factor (VEGF) Market End User, Value (US$ Mn), 2018 - 2031
4.5.1.5. Canada Vascular Endothelial Growth Factor (VEGF) Market by VEGF Types, Value (US$ Mn), 2018 - 2031
4.5.1.6. Canada Vascular Endothelial Growth Factor (VEGF) Market Indication, Value (US$ Mn), 2018 - 2031
4.5.1.7. Canada Vascular Endothelial Growth Factor (VEGF) Market Artery Type, Value (US$ Mn), 2018 - 2031
4.5.1.8. Canada Vascular Endothelial Growth Factor (VEGF) Market End User, Value (US$ Mn), 2018 - 2031
4.5.2. BPS Analysis/Market Attractiveness Analysis

5. Europe Vascular Endothelial Growth Factor (VEGF) Market Outlook, 2018 - 2031

5.1. Europe Vascular Endothelial Growth Factor (VEGF) Market Outlook, by VEGF Types, Value (US$ Mn), 2018 - 2031
5.1.1. Key Highlights
5.1.1.1. Human VEGF
5.1.1.2. Mouse VEGF
5.1.1.3. Rat VEGF
5.1.1.4. Rabbit VEGF
5.1.1.5. Others VEGF
5.2. Europe Vascular Endothelial Growth Factor (VEGF) Market Outlook, by Application, Value (US$ Mn), 2018 - 2031
5.2.1. Key Highlights
5.2.1.1. Cell Culture
5.2.1.2. Cell-based Therapy
5.2.1.3. Drug Development
5.2.1.4. Gene Therapy
5.2.1.5. Rare Disease treatment
5.2.1.6. Wound Healing Research
5.2.1.7. Combination Therapies
5.2.1.8. Hematology Research
5.2.1.9. Osteogenesis
5.2.1.10. Anti-Angiogenic Therapy
5.3. Europe Vascular Endothelial Growth Factor (VEGF) Market Outlook, by Expression Host, Value (US$ Mn), 2018 - 2031
5.3.1. Key Highlights
5.3.1.1. CHO
5.3.1.2. E. Coli
5.3.1.3. HEK
5.3.1.4. NSO
5.3.1.5. Insect Cells
5.3.1.6. Others
5.4. Europe Vascular Endothelial Growth Factor (VEGF) Market Outlook, by End User, Value (US$ Mn), 2018 - 2031
5.4.1. Key Highlights
5.4.1.1. Pharmaceutical & Biotechnology Companies
5.4.1.2. Academic Institutes
5.4.1.3. CMOs & CDMOs
5.4.1.4. Other End Users
5.4.1.4.1. Research Centers & Laboratories
5.4.1.4.2. Hospital-attached Laboratories (HALs)
5.5. Europe Vascular Endothelial Growth Factor (VEGF) Market Outlook, by Country, Value (US$ Mn), 2018 - 2031
5.5.1. Key Highlights
5.5.1.1. Germany Vascular Endothelial Growth Factor (VEGF) Market by VEGF Types, Value (US$ Mn), 2018 - 2031
5.5.1.2. Germany Vascular Endothelial Growth Factor (VEGF) Market Indication, Value (US$ Mn), 2018 - 2031
5.5.1.3. Germany Vascular Endothelial Growth Factor (VEGF) Market Artery Type, Value (US$ Mn), 2018 - 2031
5.5.1.4. Germany Vascular Endothelial Growth Factor (VEGF) Market End User, Value (US$ Mn), 2018 - 2031
5.5.1.5. U.K. Vascular Endothelial Growth Factor (VEGF) Market by VEGF Types, Value (US$ Mn), 2018 - 2031
5.5.1.6. U.K. Vascular Endothelial Growth Factor (VEGF) Market Indication, Value (US$ Mn), 2018 - 2031
5.5.1.7. U.K. Vascular Endothelial Growth Factor (VEGF) Market Artery Type, Value (US$ Mn), 2018 - 2031
5.5.1.8. U.K. Vascular Endothelial Growth Factor (VEGF) Market End User, Value (US$ Mn), 2018 - 2031
5.5.1.9. France Vascular Endothelial Growth Factor (VEGF) Market by VEGF Types, Value (US$ Mn), 2018 - 2031
5.5.1.10. France Vascular Endothelial Growth Factor (VEGF) Market Indication, Value (US$ Mn), 2018 - 2031
5.5.1.11. France Vascular Endothelial Growth Factor (VEGF) Market Artery Type, Value (US$ Mn), 2018 - 2031
5.5.1.12. France Vascular Endothelial Growth Factor (VEGF) Market End User, Value (US$ Mn), 2018 - 2031
5.5.1.13. Italy Vascular Endothelial Growth Factor (VEGF) Market by VEGF Types, Value (US$ Mn), 2018 - 2031
5.5.1.14. Italy Vascular Endothelial Growth Factor (VEGF) Market Indication, Value (US$ Mn), 2018 - 2031
5.5.1.15. Italy Vascular Endothelial Growth Factor (VEGF) Market Artery Type, Value (US$ Mn), 2018 - 2031
5.5.1.16. Italy Vascular Endothelial Growth Factor (VEGF) Market End User, Value (US$ Mn), 2018 - 2031
5.5.1.17. Turkey Vascular Endothelial Growth Factor (VEGF) Market by VEGF Types, Value (US$ Mn), 2018 - 2031
5.5.1.18. Turkey Vascular Endothelial Growth Factor (VEGF) Market Indication, Value (US$ Mn), 2018 - 2031
5.5.1.19. Turkey Vascular Endothelial Growth Factor (VEGF) Market Artery Type, Value (US$ Mn), 2018 - 2031
5.5.1.20. Turkey Vascular Endothelial Growth Factor (VEGF) Market End User, Value (US$ Mn), 2018 - 2031
5.5.1.21. Russia Vascular Endothelial Growth Factor (VEGF) Market by VEGF Types, Value (US$ Mn), 2018 - 2031
5.5.1.22. Russia Vascular Endothelial Growth Factor (VEGF) Market Indication, Value (US$ Mn), 2018 - 2031
5.5.1.23. Russia Vascular Endothelial Growth Factor (VEGF) Market Artery Type, Value (US$ Mn), 2018 - 2031
5.5.1.24. Russia Vascular Endothelial Growth Factor (VEGF) Market End User, Value (US$ Mn), 2018 - 2031
5.5.1.25. Rest of Europe Vascular Endothelial Growth Factor (VEGF) Market by VEGF Types, Value (US$ Mn), 2018 - 2031
5.5.1.26. Rest of Europe Vascular Endothelial Growth Factor (VEGF) Market Indication, Value (US$ Mn), 2018 - 2031
5.5.1.27. Rest of Europe Vascular Endothelial Growth Factor (VEGF) Market Artery Type, Value (US$ Mn), 2018 - 2031
5.5.1.28. Rest of Europe Vascular Endothelial Growth Factor (VEGF) Market End User, Value (US$ Mn), 2018 - 2031
5.5.2. BPS Analysis/Market Attractiveness Analysis

6. Asia Pacific Vascular Endothelial Growth Factor (VEGF) Market Outlook, 2018 - 2031

6.1. Asia Pacific Vascular Endothelial Growth Factor (VEGF) Market Outlook, by VEGF Types, Value (US$ Mn), 2018 - 2031
6.1.1. Key Highlights
6.1.1.1. Human VEGF
6.1.1.2. Mouse VEGF
6.1.1.3. Rat VEGF
6.1.1.4. Rabbit VEGF
6.1.1.5. Others VEGF
6.2. Asia Pacific Vascular Endothelial Growth Factor (VEGF) Market Outlook, by Application, Value (US$ Mn), 2018 - 2031
6.2.1. Key Highlights
6.2.1.1. Cell Culture
6.2.1.2. Cell-based Therapy
6.2.1.3. Drug Development
6.2.1.4. Gene Therapy
6.2.1.5. Rare Disease treatment
6.2.1.6. Wound Healing Research
6.2.1.7. Combination Therapies
6.2.1.8. Hematology Research
6.2.1.9. Osteogenesis
6.2.1.10. Anti-Angiogenic Therapy
6.3. Asia Pacific Vascular Endothelial Growth Factor (VEGF) Market Outlook, by Expression Host, Value (US$ Mn), 2018 - 2031
6.3.1. Key Highlights
6.3.1.1. CHO
6.3.1.2. E. Coli
6.3.1.3. HEK
6.3.1.4. NSO
6.3.1.5. Insect Cells
6.3.1.6. Others
6.4. Asia Pacific Vascular Endothelial Growth Factor (VEGF) Market Outlook, by End User, Value (US$ Mn), 2018 - 2031
6.4.1. Key Highlights
6.4.1.1. Pharmaceutical & Biotechnology Companies
6.4.1.2. Academic Institutes
6.4.1.3. CMOs & CDMOs
6.4.1.4. Other End Users
6.4.1.4.1. Research Centers & Laboratories
6.4.1.4.2. Hospital-attached Laboratories (HALs)
6.5. Asia Pacific Vascular Endothelial Growth Factor (VEGF) Market Outlook, by Country, Value (US$ Mn), 2018 - 2031
6.5.1. Key Highlights
6.5.1.1. China Vascular Endothelial Growth Factor (VEGF) Market by VEGF Types, Value (US$ Mn), 2018 - 2031
6.5.1.2. China Vascular Endothelial Growth Factor (VEGF) Market Indication, Value (US$ Mn), 2018 - 2031
6.5.1.3. China Vascular Endothelial Growth Factor (VEGF) Market Artery Type, Value (US$ Mn), 2018 - 2031
6.5.1.4. China Vascular Endothelial Growth Factor (VEGF) Market End User, Value (US$ Mn), 2018 - 2031
6.5.1.5. Japan Vascular Endothelial Growth Factor (VEGF) Market by VEGF Types, Value (US$ Mn), 2018 - 2031
6.5.1.6. Japan Vascular Endothelial Growth Factor (VEGF) Market Indication, Value (US$ Mn), 2018 - 2031
6.5.1.7. Japan Vascular Endothelial Growth Factor (VEGF) Market Artery Type, Value (US$ Mn), 2018 - 2031
6.5.1.8. Japan Vascular Endothelial Growth Factor (VEGF) Market End User, Value (US$ Mn), 2018 - 2031
6.5.1.9. South Korea Vascular Endothelial Growth Factor (VEGF) Market by VEGF Types, Value (US$ Mn), 2018 - 2031
6.5.1.10. South Korea Vascular Endothelial Growth Factor (VEGF) Market Indication, Value (US$ Mn), 2018 - 2031
6.5.1.11. South Korea Vascular Endothelial Growth Factor (VEGF) Market Artery Type, Value (US$ Mn), 2018 - 2031
6.5.1.12. South Korea Vascular Endothelial Growth Factor (VEGF) Market End User, Value (US$ Mn), 2018 - 2031
6.5.1.13. India Vascular Endothelial Growth Factor (VEGF) Market by VEGF Types, Value (US$ Mn), 2018 - 2031
6.5.1.14. India Vascular Endothelial Growth Factor (VEGF) Market Indication, Value (US$ Mn), 2018 - 2031
6.5.1.15. India Vascular Endothelial Growth Factor (VEGF) Market Artery Type, Value (US$ Mn), 2018 - 2031
6.5.1.16. India Vascular Endothelial Growth Factor (VEGF) Market End User, Value (US$ Mn), 2018 - 2031
6.5.1.17. Southeast Asia Vascular Endothelial Growth Factor (VEGF) Market by VEGF Types, Value (US$ Mn), 2018 - 2031
6.5.1.18. Southeast Asia Vascular Endothelial Growth Factor (VEGF) Market Indication, Value (US$ Mn), 2018 - 2031
6.5.1.19. Southeast Asia Vascular Endothelial Growth Factor (VEGF) Market Artery Type, Value (US$ Mn), 2018 - 2031
6.5.1.20. Southeast Asia Vascular Endothelial Growth Factor (VEGF) Market End User, Value (US$ Mn), 2018 - 2031
6.5.1.21. Rest of Asia Pacific Vascular Endothelial Growth Factor (VEGF) Market by VEGF Types, Value (US$ Mn), 2018 - 2031
6.5.1.22. Rest of Asia Pacific Vascular Endothelial Growth Factor (VEGF) Market Indication, Value (US$ Mn), 2018 - 2031
6.5.1.23. Rest of Asia Pacific Vascular Endothelial Growth Factor (VEGF) Market Artery Type, Value (US$ Mn), 2018 - 2031
6.5.1.24. Rest of Asia Pacific Vascular Endothelial Growth Factor (VEGF) Market End User, Value (US$ Mn), 2018 - 2031
6.5.2. BPS Analysis/Market Attractiveness Analysis

7. Latin America Vascular Endothelial Growth Factor (VEGF) Market Outlook, 2018 - 2031

7.1. Latin America Vascular Endothelial Growth Factor (VEGF) Market Outlook, by VEGF Types, Value (US$ Mn), 2018 - 2031
7.1.1. Key Highlights
7.1.1.1. Human VEGF
7.1.1.2. Mouse VEGF
7.1.1.3. Rat VEGF
7.1.1.4. Rabbit VEGF
7.1.1.5. Others VEGF
7.2. Latin America Vascular Endothelial Growth Factor (VEGF) Market Outlook, by Application, Value (US$ Mn), 2018 - 2031
7.2.1.1. Cell Culture
7.2.1.2. Cell-based Therapy
7.2.1.3. Drug Development
7.2.1.4. Gene Therapy
7.2.1.5. Rare Disease treatment
7.2.1.6. Wound Healing Research
7.2.1.7. Combination Therapies
7.2.1.8. Hematology Research
7.2.1.9. Osteogenesis
7.2.1.10. Anti-Angiogenic Therapy
7.3. Latin America Vascular Endothelial Growth Factor (VEGF) Market Outlook, by Expression Host, Value (US$ Mn), 2018 - 2031
7.3.1. Key Highlights
7.3.1.1. CHO
7.3.1.2. E. Coli
7.3.1.3. HEK
7.3.1.4. NSO
7.3.1.5. Insect Cells
7.3.1.6. Others
7.4. Latin America Vascular Endothelial Growth Factor (VEGF) Market Outlook, by End User, Value (US$ Mn), 2018 - 2031
7.4.1. Key Highlights
7.4.1.1. Pharmaceutical & Biotechnology Companies
7.4.1.2. Academic Institutes
7.4.1.3. CMOs & CDMOs
7.4.1.4. Other End Users
7.4.1.4.1. Research Centers & Laboratories
7.4.1.4.2. Hospital-attached Laboratories (HALs)
7.5. Latin America Vascular Endothelial Growth Factor (VEGF) Market Outlook, by Country, Value (US$ Mn), 2018 - 2031
7.5.1. Key Highlights
7.5.1.1. Brazil Vascular Endothelial Growth Factor (VEGF) Market by VEGF Types, Value (US$ Mn), 2018 - 2031
7.5.1.2. Brazil Vascular Endothelial Growth Factor (VEGF) Market Indication, Value (US$ Mn), 2018 - 2031
7.5.1.3. Brazil Vascular Endothelial Growth Factor (VEGF) Market Artery Type, Value (US$ Mn), 2018 - 2031
7.5.1.4. Brazil Vascular Endothelial Growth Factor (VEGF) Market End User, Value (US$ Mn), 2018 - 2031
7.5.1.5. Mexico Vascular Endothelial Growth Factor (VEGF) Market by VEGF Types, Value (US$ Mn), 2018 - 2031
7.5.1.6. Mexico Vascular Endothelial Growth Factor (VEGF) Market Indication, Value (US$ Mn), 2018 - 2031
7.5.1.7. Mexico Vascular Endothelial Growth Factor (VEGF) Market Artery Type, Value (US$ Mn), 2018 - 2031
7.5.1.8. Mexico Vascular Endothelial Growth Factor (VEGF) Market End User, Value (US$ Mn), 2018 - 2031
7.5.1.9. Argentina Vascular Endothelial Growth Factor (VEGF) Market by VEGF Types, Value (US$ Mn), 2018 - 2031
7.5.1.10. Argentina Vascular Endothelial Growth Factor (VEGF) Market Indication, Value (US$ Mn), 2018 - 2031
7.5.1.11. Argentina Vascular Endothelial Growth Factor (VEGF) Market Artery Type, Value (US$ Mn), 2018 - 2031
7.5.1.12. Argentina Vascular Endothelial Growth Factor (VEGF) Market End User, Value (US$ Mn), 2018 - 2031
7.5.1.13. Rest of Latin America Vascular Endothelial Growth Factor (VEGF) Market by VEGF Types, Value (US$ Mn), 2018 - 2031
7.5.1.14. Rest of Latin America Vascular Endothelial Growth Factor (VEGF) Market Indication, Value (US$ Mn), 2018 - 2031
7.5.1.15. Rest of Latin America Vascular Endothelial Growth Factor (VEGF) Market Artery Type, Value (US$ Mn), 2018 - 2031
7.5.1.16. Rest of Latin America Vascular Endothelial Growth Factor (VEGF) Market End User, Value (US$ Mn), 2018 - 2031
7.5.2. BPS Analysis/Market Attractiveness Analysis

8. Middle East & Africa Vascular Endothelial Growth Factor (VEGF) Market Outlook, 2018 - 2031

8.1. Middle East & Africa Vascular Endothelial Growth Factor (VEGF) Market Outlook, by VEGF Types, Value (US$ Mn), 2018 - 2031
8.1.1. Key Highlights
8.1.1.1. Human VEGF
8.1.1.2. Mouse VEGF
8.1.1.3. Rat VEGF
8.1.1.4. Rabbit VEGF
8.1.1.5. Others VEGF
8.2. Middle East & Africa Vascular Endothelial Growth Factor (VEGF) Market Outlook, by Application, Value (US$ Mn), 2018 - 2031
8.2.1. Key Highlights
8.2.1.1. Cell Culture
8.2.1.2. Cell-based Therapy
8.2.1.3. Drug Development
8.2.1.4. Gene Therapy
8.2.1.5. Rare Disease treatment
8.2.1.6. Wound Healing Research
8.2.1.7. Combination Therapies
8.2.1.8. Hematology Research
8.2.1.9. Osteogenesis
8.2.1.10. Anti-Angiogenic Therapy
8.3. Middle East & Africa Vascular Endothelial Growth Factor (VEGF) Market Outlook, by Expression Host, Value (US$ Mn), 2018 - 2031
8.3.1. Key Highlights
8.3.1.1. CHO
8.3.1.2. E. Coli
8.3.1.3. HEK
8.3.1.4. NSO
8.3.1.5. Insect Cells
8.3.1.6. Others
8.4. Middle East & Africa Vascular Endothelial Growth Factor (VEGF) Market Outlook, by End User, Value (US$ Mn), 2018 - 2031
8.4.1. Key Highlights
8.4.1.1. Pharmaceutical & Biotechnology Companies
8.4.1.2. Academic Institutes
8.4.1.3. CMOs & CDMOs
8.4.1.4. Other End Users
8.4.1.4.1. Research Centers & Laboratories
8.4.1.4.2. Hospital-attached Laboratories (HALs)
8.5. Middle East & Africa Vascular Endothelial Growth Factor (VEGF) Market Outlook, by Country, Value (US$ Mn), 2018 - 2031
8.5.1. Key Highlights
8.5.1.1. GCC Vascular Endothelial Growth Factor (VEGF) Market by VEGF Types, Value (US$ Mn), 2018 - 2031
8.5.1.2. GCC Vascular Endothelial Growth Factor (VEGF) Market Indication, Value (US$ Mn), 2018 - 2031
8.5.1.3. GCC Vascular Endothelial Growth Factor (VEGF) Market Artery Type, Value (US$ Mn), 2018 - 2031
8.5.1.4. GCC Vascular Endothelial Growth Factor (VEGF) Market End User, Value (US$ Mn), 2018 - 2031
8.5.1.5. South Africa Vascular Endothelial Growth Factor (VEGF) Market by VEGF Types, Value (US$ Mn), 2018 - 2031
8.5.1.6. South Africa Vascular Endothelial Growth Factor (VEGF) Market Indication, Value (US$ Mn), 2018 - 2031
8.5.1.7. South Africa Vascular Endothelial Growth Factor (VEGF) Market Artery Type, Value (US$ Mn), 2018 - 2031
8.5.1.8. South Africa Vascular Endothelial Growth Factor (VEGF) Market End User, Value (US$ Mn), 2018 - 2031
8.5.1.9. Egypt Vascular Endothelial Growth Factor (VEGF) Market by VEGF Types, Value (US$ Mn), 2018 - 2031
8.5.1.10. Egypt Vascular Endothelial Growth Factor (VEGF) Market Indication, Value (US$ Mn), 2018 - 2031
8.5.1.11. Egypt Vascular Endothelial Growth Factor (VEGF) Market Artery Type, Value (US$ Mn), 2018 - 2031
8.5.1.12. Egypt Vascular Endothelial Growth Factor (VEGF) Market End User, Value (US$ Mn), 2018 - 2031
8.5.1.13. Nigeria Vascular Endothelial Growth Factor (VEGF) Market by VEGF Types, Value (US$ Mn), 2018 - 2031
8.5.1.14. Nigeria Vascular Endothelial Growth Factor (VEGF) Market Indication, Value (US$ Mn), 2018 - 2031
8.5.1.15. Nigeria Vascular Endothelial Growth Factor (VEGF) Market Artery Type, Value (US$ Mn), 2018 - 2031
8.5.1.16. Nigeria Vascular Endothelial Growth Factor (VEGF) Market End User, Value (US$ Mn), 2018 - 2031
8.5.1.17. Rest of Middle East & Africa Vascular Endothelial Growth Factor (VEGF) Market by VEGF Types, Value (US$ Mn), 2018 - 2031
8.5.1.18. Rest of Middle East & Africa Vascular Endothelial Growth Factor (VEGF) Market Indication, Value (US$ Mn), 2018 - 2031
8.5.1.19. Rest of Middle East & Africa Vascular Endothelial Growth Factor (VEGF) Market Artery Type, Value (US$ Mn), 2018 - 2031
8.5.1.20. Rest of Middle East & Africa Vascular Endothelial Growth Factor (VEGF) Market End User, Value (US$ Mn), 2018 - 2031
8.5.2. BPS Analysis/Market Attractiveness Analysis

9. Competitive Landscape

9.1. Artery Type vs Indication Heatmap
9.2. Manufacturer vs Indication Heatmap
9.3. Company Market Share Analysis, 2023
9.4. Competitive Dashboard
9.5. Company Profiles
9.5.1. Thermo Fisher Scientific Inc.
9.5.1.1. Company Overview
9.5.1.2. Product Portfolio
9.5.1.3. Financial Overview
9.5.1.4. Business Strategies and Development
9.5.2. Merck KGaA
9.5.2.1. Company Overview
9.5.2.2. Product Portfolio
9.5.2.3. Financial Overview
9.5.2.4. Business Strategies and Development
9.5.3. Bio-Rad Laboratories, Inc.
9.5.3.1. Company Overview
9.5.3.2. Product Portfolio
9.5.3.3. Financial Overview
9.5.3.4. Business Strategies and Development
9.5.4. Bio-Techne [R&D Systems, Inc.]
9.5.4.1. Company Overview
9.5.4.2. Product Portfolio
9.5.4.3. Financial Overview
9.5.4.4. Business Strategies and Development
9.5.5. GenScript
9.5.5.1. Company Overview
9.5.5.2. Product Portfolio
9.5.5.3. Financial Overview
9.5.5.4. Business Strategies and Development
9.5.6. Miltenyi Biotec.
9.5.6.1. Company Overview
9.5.6.2. Product Portfolio
9.5.6.3. Financial Overview
9.5.6.4. Business Strategies and Development
9.5.7. Abcam PLC.
9.5.7.1. Company Overview
9.5.7.2. Product Portfolio
9.5.7.3. Financial Overview
9.5.7.4. Business Strategies and Development
9.5.8. Sino Biological Inc.
9.5.8.1. Company Overview
9.5.8.2. Product Portfolio
9.5.8.3. Financial Overview
9.5.8.4. Business Strategies and Development
9.5.9. Cell Signaling Technology, Inc.
9.5.9.1. Company Overview
9.5.9.2. Product Portfolio
9.5.9.3. Financial Overview
9.5.9.4. Business Strategies and Development
9.5.10. ACROBiosystems
9.5.10.1. Company Overview
9.5.10.2. Product Portfolio
9.5.10.3. Financial Overview
9.5.10.4. Business Strategies and Development
9.5.11. STEMCELL Technologies
9.5.11.1. Company Overview
9.5.11.2. Product Portfolio
9.5.11.3. Financial Overview
9.5.11.4. Business Strategies and Development
9.5.12. Creative Bioarray
9.5.12.1. Company Overview
9.5.12.2. Product Portfolio
9.5.12.3. Financial Overview
9.5.12.4. Business Strategies and Development
9.5.13. PeproTech
9.5.13.1. Company Overview
9.5.13.2. Product Portfolio
9.5.13.3. Financial Overview
9.5.13.4. Business Strategies and Development
9.5.14. Applied Biological Materials (ABM) Inc.
9.5.14.1. Company Overview
9.5.14.2. Product Portfolio
9.5.14.3. Financial Overview
9.5.14.4. Business Strategies and Development
9.5.15. AMG International GmbH
9.5.15.1. Company Overview
9.5.15.2. Product Portfolio
9.5.15.3. Financial Overview
9.5.15.4. Business Strategies and Development
9.5.16. GenWay Biotech
9.5.16.1. Company Overview
9.5.16.2. Product Portfolio
9.5.16.3. Financial Overview
9.5.16.4. Business Strategies and Development
9.5.17. Leadgene Biomedical, Inc.
9.5.17.1. Company Overview
9.5.17.2. Product Portfolio
9.5.17.3. Financial Overview
9.5.17.4. Business Strategies and Development
9.5.18. Boster Bio
9.5.18.1. Company Overview
9.5.18.2. Product Portfolio
9.5.18.3. Financial Overview
9.5.18.4. Business Strategies and Development
9.5.19. Prospec-Tany Technogene Ltd.
9.5.19.1. Company Overview
9.5.19.2. Product Portfolio
9.5.19.3. Financial Overview
9.5.19.4. Business Strategies and Development
9.5.20. Proteintech Group, Inc
9.5.20.1. Company Overview
9.5.20.2. Product Portfolio
9.5.20.3. Financial Overview
9.5.20.4. Business Strategies and Development

10. Appendix

10.1. Research Methodology
10.2. Report Assumptions
10.3. Acronyms and Abbreviations

Companies Mentioned (Partial List)

A selection of companies mentioned in this report includes, but is not limited to:

Thermo Fisher Scientific
Merck KGaA
Bio-Rad Laboratories, Inc.
Bio-Techne [R&D Systems, Inc.]
GenScript
Miltenyi Biotec.
Abcam PLC.
Sino Biological Inc.
Cell Signaling Technology, Inc.
ACROBiosystems
STEMCELL Technologies
Creative Bioarray
PeproTech
Applied Biological Materials (abm) Inc.
GenWay Biotech
Leadgene Biomedical, Inc.
Boster Bio
Prospec-Tany Technogene Ltd.
Proteintech Group, Inc

Methodology

LOADING...

A Pivotal Role in Disease Intervention

Opportunities for VEGF Manufacturers

Challenges in VEGF Market Expansion

Country-wise Insights

Competitive Landscape

Key Segments Covered in VEGF Industry Survey

VEGF Market by VEGF Type:

VEGF Market by Expression Host:

VEGF Market by Application:

VEGF Market by End User:

VEGF Market by Region:

Table of Contents

Companies Mentioned (Partial List)

Methodology

Related Topics

Related Reports

Anti-Vascular Endothelial Growth Factor Therapeutics Market - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast 2031 - By Product, Technology, Grade, Application, End-user, Region: (North America, Europe, Asia Pacific, Latin America and Middle East and Africa)

Anti-Vascular Endothelial Growth Factor Therapeutics Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, 2019-2029F

Vascular endothelial growth factor A inhibitors - Pipeline Insight, 2024

Vascular endothelial growth factor receptor-2 antagonists - Pipeline Insight, 2024

Anti-Vascular Endothelial Growth Factor Therapeutics Global Market Report 2024